As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here's the latest list of major overbought players in this sector.

Doximity Inc (NYSE:DOCS)

• On Aug. 8, Doximity reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates. "We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines," said Jeff Tangney, co-founder and CEO of Doximity. "Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save time and better serve their patients." The company's stock gained around 13% over the past month and has a 52-week high of $41.69.
• RSI Value: 82.05
• DOCS Price Action: Shares of Doximity gained 1.4% to close at $41.50 on Monday.

Gilead Sciences, Inc. (NASDAQ:GILD)

• Gilead Sciences voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials. The company's stock gained around 9% over the past month and has a 52-week high of $87.86.
• RSI Value: 72.77
• GILD Price Action: Shares of Gilead Sciences rose 0.1% to close at $83.99 on Monday.

Genfit SA (NASDAQ:GNFT)

• On Sept. 19, Genfit posted H1 2024 adjusted EPS of €0.53 and revenues and other income of €61.199 million. The company's stock gained around 15% over the past five days and has a 52-week high of $6.05.
• RSI Value: 70.41
• GNFT Price Action: Shares of Genfit rose 3.1% to close at $4.99 on Monday.

Bullfrog AI Holdings, Inc (NASDAQ:BFRG)

• On July 25, BullFrog AI announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development for specific molecular pathways associated with bipolar disorder, enabling the identification of new candidate drug targets. The company's stock has a 52-week high is $8.35.
• RSI Value: 78.66
• BFRG Price Action: Shares of Bullfrog AI gained 32.4% to close at $3.19 on Monday.

Read More:

• Jim Cramer Says This Utilities Stock Is A Buy: 'We Need Cheap Power'